Barclays PLC Has $524,000 Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Barclays PLC raised its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 201.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,107 shares of the company's stock after buying an additional 20,107 shares during the period. Barclays PLC owned about 0.06% of Bicara Therapeutics worth $524,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth $31,000. Legal & General Group Plc bought a new position in shares of Bicara Therapeutics in the 4th quarter valued at about $33,000. Summit Investment Advisors Inc. bought a new stake in shares of Bicara Therapeutics during the fourth quarter worth approximately $35,000. SG Americas Securities LLC acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $147,000. Finally, Corebridge Financial Inc. acquired a new stake in Bicara Therapeutics during the 4th quarter worth $167,000.

Bicara Therapeutics Stock Performance

BCAX stock traded up $1.22 during mid-day trading on Monday, hitting $14.19. 567,900 shares of the company were exchanged, compared to its average volume of 487,567. Bicara Therapeutics Inc. has a 1-year low of $8.91 and a 1-year high of $28.09. The firm's 50 day simple moving average is $12.95 and its 200 day simple moving average is $15.52.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). On average, analysts expect that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on BCAX. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reissued an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. HC Wainwright reduced their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a report on Monday, April 7th. Wells Fargo & Company initiated coverage on shares of Bicara Therapeutics in a report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price objective for the company. Finally, Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $32.43.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.